U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07159009) titled 'A Study of GB261 in Systemic Sclerosis' on Aug. 25.
Brief Summary: The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of GB261 in patients with SSc.
Study Start Date: Sept. 04
Study Type: INTERVENTIONAL
Condition:
Systemic Sclerosis (SSc)
Intervention:
DRUG: Biological: GB261
GB261 will be dosed according to the protocol
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ruijin Hospital
Published by HT Digital Content Services with permission from Health Daily Digest....